{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:13:45Z","timestamp":1788509625933,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104351","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:36:18Z","timestamp":1780500978000},"page":"104351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of pneumatic tube system transportation on product quality of therapeutic monoclonal antibody lyophilized and reconstituted drug products"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-3803","authenticated-orcid":false,"given":"Kashappa Goud","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7585-8671","authenticated-orcid":false,"given":"Cait","family":"Sofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-3751","authenticated-orcid":false,"given":"James D.","family":"Colandene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Heacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elnabawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6144-9288","authenticated-orcid":false,"given":"Brendan","family":"Blockus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Jirwankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bivash","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2026.104351_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COH.0000000000000154","article-title":"History of passive antibody administration for prevention and treatment of infectious diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"10.1016\/j.xphs.2026.104351_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, cars and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.xphs.2026.104351_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6116","key":"10.1016\/j.xphs.2026.104351_bib0004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.1230720","article-title":"Anti-inflammatory therapy in chronic disease: challenges and opportunities","volume":"339","author":"Tabas","year":"2013","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.xphs.2026.104351_bib0005","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharm Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104351_bib0006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.xphs.2026.104351_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/antib11030056","article-title":"Alternative routes of administration for therapeutic antibodies-state of the art","volume":"11","author":"Pitiot","year":"2022","journal-title":"Antibodies"},{"issue":"11","key":"10.1016\/j.xphs.2026.104351_bib0008","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/aps.2012.51","article-title":"Clinical pharmacology considerations in biologics development","volume":"33","author":"Zhao","year":"2012","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"10.1016\/j.xphs.2026.104351_bib0009","first-page":"52","article-title":"Pneumatic tube systems for ever-changing marketplace","volume":"55","author":"Foxley","year":"2001","journal-title":"Health Estate"},{"key":"10.1016\/j.xphs.2026.104351_bib0010","unstructured":"Pneumatic-tube-system-basics. https:\/\/www.youtube.com\/watch?v=gAlzYLcqsTU."},{"key":"10.1016\/j.xphs.2026.104351_bib0011","unstructured":"Weinmeyer M. The pneumatic tube \u2013 this is how it works. https:\/\/www.swisslog-healthcare.com\/en-gb\/company\/blog\/how-a-pneumatic-tube-system-works#:\u223c:text=The%20pneumatic%20tube%20in%20hospitals&text=The%20pneumatic%20tube%20system%20ideally,the%20hospital%20%E2%80%93%20diagnostics%20and%20therapy, (accessed 2026-06-06)."},{"issue":"4","key":"10.1016\/j.xphs.2026.104351_bib0012","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.xphs.2022.01.016","article-title":"Effects of transportation of IV bags containing protein formulations via hospital pneumatic tube system: particle characterization by multiple methods","volume":"111","author":"Linkuvien\u0117","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104351_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106952","article-title":"Impact of pneumatic tube transportation on the aggregation of monoclonal antibodies in clinical practice","volume":"204","author":"Cohrs","year":"2025","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104351_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49235-6","article-title":"Influence of pneumatic transportation on the stability of monoclonal antibodies","volume":"13","author":"Coliat","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0015","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.xphs.2024.12.003","article-title":"Pneumatic tube transport of trastuzumab in IV bags\u2014effect of headspace and surfactant on subvisible particle formation","volume":"114","author":"Kjellstr\u00f6m","year":"2025","journal-title":"J Pharm Sci"},{"issue":"18","key":"10.1016\/j.xphs.2026.104351_bib0016","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/ajhp\/zxab196","article-title":"Transportation of a commercial premixed intravenous insulin product through a pneumatic tube system","volume":"78","author":"Leja","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104351_bib0017","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1021\/acs.molpharmaceut.3c00859","article-title":"Transportation of mAb dosing solution in intravenous bag: impact of manual, vehicle, and pneumatic tube system transportation methods on product quality","volume":"20","author":"Desai","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104351_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103715","article-title":"Transportation of protein drugs at hospital: comparison of mechanical stress occurring during pneumatic transportation and hand-carried transport","author":"Barreau","year":"2025","journal-title":"J Pharmaceut Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104351_bib0019","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1021\/acs.molpharmaceut.5c00428","article-title":"A novel laboratory-scale pneumatic tube system (PTS) transportation model to assess the impact of hospital PTS transportation on the product quality of therapeutic monoclonal antibodies","volume":"22","author":"Desai","year":"2025","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jps.24242","article-title":"Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress","volume":"104","author":"Telikepalli","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104351_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2018.09.057","article-title":"Unexplored benefits of controlled ice nucleation: lyophilization of a highly concentrated monoclonal antibody solution","volume":"552","author":"Singh","year":"2018","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104351_bib0022","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.xphs.2016.11.021","article-title":"Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies","volume":"106","author":"Fleischman","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104351_bib0023","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.xphs.2022.05.002","article-title":"Identification of agitation-induced unfolding events causing aggregation of monoclonal antibodies using hydrogen exchange-mass spectrometry","volume":"111","author":"Gamage","year":"2022","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2026.104351_bib0024","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1002\/jps.21328","article-title":"Shaken, not stirred: mechanical stress testing of an IgG1 antibody","volume":"97","author":"Kiese","year":"2008","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104351_bib0025","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/jps.23622","article-title":"The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study","volume":"102","author":"Liu","year":"2013","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bit.27212","article-title":"Synergistic effects of flow and interfaces on antibody aggregation","volume":"117","author":"Grigolato","year":"2020","journal-title":"Biotechnol Bioeng"},{"issue":"9","key":"10.1016\/j.xphs.2026.104351_bib0027","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1021\/acs.molpharmaceut.2c00152","article-title":"Differential surface adsorption phenomena for conventional and novel surfactants correlates with changes in interfacial mAb stabilization","volume":"19","author":"Kanthe","year":"2022","journal-title":"Mol Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104351_bib0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2017.12.043","article-title":"Notorious but not understood: how liquid-air interfacial stress triggers protein aggregation","volume":"537","author":"Koepf","year":"2018","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104351_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12248-019-0312-3","article-title":"Interfacial stress in the development of biologics: fundamental understanding, current practice, and future perspective","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104351_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121706","article-title":"Poloxamer 188 as surfactant in biological formulations \u2013 an alternative for polysorbate 20\/80?","volume":"620","author":"Bollenbach","year":"2022","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104351_bib0031","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jps.23907","article-title":"Modulation of protein adsorption by poloxamer 188 in relation to polysorbates 80 and 20 at solid surfaces","volume":"103","author":"Kim","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104351_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124374","article-title":"Effect of surfactants on lactate dehydrogenase aqueous solutions: a comparative study of poloxamer 188, polysorbate 20 and 80","volume":"661","author":"Li","year":"2024","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2026.104351_bib0033","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.xphs.2022.08.021","article-title":"Industry perspective on the use and characterization of polysorbates for biopharmaceutical products part 2: survey report on control strategy preparing for the future","volume":"111","author":"Wuchner","year":"2022","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104351_bib0034","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.xphs.2022.02.009","article-title":"Industry perspective on the use and characterization of polysorbates for biopharmaceutical products part 1: survey report on current state and common practices for handling and control of polysorbates","volume":"111","author":"Wuchner","year":"2022","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104351_bib0035","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.xphs.2023.06.004","article-title":"Comparison of the protective effect of polysorbates, poloxamer and Brij on antibody stability against different interfaces","volume":"112","author":"Z\u00fcrcher","year":"2023","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104351_bib0036","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jps.20365","article-title":"Effects of Tween 20\u00ae and Tween 80\u00ae on the stability of albutropin during agitation","volume":"94","author":"Chou","year":"2005","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0037","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.xphs.2016.09.028","article-title":"Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product","volume":"106","author":"Pardeshi","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0038","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jps.24259","article-title":"Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation","volume":"104","author":"Randolph","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104351_bib0039","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.xphs.2019.06.015","article-title":"DEHP nanodroplets leached from polyvinyl chloride IV bags promote aggregation of IVIG and activate complement in human serum","volume":"109","author":"Snell","year":"2020","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104351_bib0040","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1002\/jps.21575","article-title":"Quantitation of protein particles in parenteral solutions using micro-flow imaging","volume":"98","author":"Huang","year":"2009","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104351_bib0041","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.xphs.2018.08.006","article-title":"Collaborative study for analysis of subvisible particles using flow imaging and light obscuration: experiences in Japanese biopharmaceutical consortium","volume":"108","author":"Kiyoshi","year":"2019","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104351_bib0042","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.xphs.2019.02.019","article-title":"Variance between different light obscuration and flow imaging microscopy instruments and the impact of instrument calibration","volume":"108","author":"Matter","year":"2019","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104351_bib0043","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-010-9205-1","article-title":"Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations","volume":"12","author":"Sharma","year":"2010","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.xphs.2026.104351_bib0044","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.xphs.2022.03.002","article-title":"Freeze-dried monoclonal antibody formulations are unexpectedly more prone to degradation than liquid formulations under shaking stress","volume":"111","author":"Fang","year":"2022","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:33:51Z","timestamp":1788507231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926002005"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104351","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pneumatic tube system transportation on product quality of therapeutic monoclonal antibody lyophilized and reconstituted drug products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104351"}}